Top Ten articles in the pharma industry this week
October 14, 2016Medical Communications news, october, pharmaceutical, top 10, top ten, top ten stories
This week has seen a lot of news regarding specific drugs going through trial and some impressive results within. Read …
Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal
October 14, 2016Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD
Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …
NICE plans new “fast-track” appraisal option
October 14, 2016Medical Communications, Sales and Marketing NHS, NICE
The National Institute for Health and Care Excellence (NICE) has proposed the introduction of a fast-track process which could make …
NICE knocks back Janssen rare disease drug
October 13, 2016Medical Communications Janssen, NICE, imbruvica
NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …
Pfizer loses UK patent infringement case over $5.1bn drug
October 13, 2016Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, patent infringement, pregabalin
Pfizer has been dealt a significant blow as the UK Court of Appeal has rejected the company’s patent infringement claims …
Nordic Nanovector announces the appointment of Joanna Horobin as Non-Executive Board Director
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nordic Nanovector, appointment, norway
Nordic Nanovector announced on 12 October that Joanna Horobin was elected to its Board as non-executive director at the company’s …
Merck KgaA foresees meeting 2018 objectives and plans for 2022
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, 2022, Germany, Merck KGaA
Speaking at its 2016 Capital Market Day about the progress it had made towards its 2018 objectives, CEO Stefan Oschmann …
Sanofi lowers Q3 sales figures from 2015
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results
Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …
New treatment for leukaemia nullifies cancer cells
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia
New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …
Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, India, US, america, sun pharmaceutical
Sun Pharmaceuticals have been forced to recall 31,762 bottles of anti-depressants from the US market after the FDA issued a …
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health
October 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle
The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Gamida Cell receives Breakthrough Therapy Designation from FDA
October 12, 2016Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma
Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …
Transgene announce key partnership with Merck KGaA and Pfizer
October 12, 2016Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck
Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
NICE backs Celgene’s Otezla for psoriatic arthritis
October 12, 2016Research and Development, Sales and Marketing Celgene, NICE, otezla
The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …
AstraZeneca forced to abandon Phase II trial
October 12, 2016Research and Development AstraZeneca, Synairgen, asthma, cold, common cold
Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …
Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare
October 11, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …
Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial
October 11, 2016Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
Nordic Nanovector and LegoChem Biosciences enter into collaboration
October 11, 2016Manufacturing and Production
The Norwegian company Nordic Nanovector and the South Korean company LegoChem Biosciences have begun a collaboration to develop novel CD37-targeting …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
